Replies to post #20983 on Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

PROVISTA TO GO PUBLIC with breast, lung cancer testing technology

www.azbio.org/provista-to-go-public-with-breast-lung-cancer-testing-technology

You Said

"Nobody is claiming that Provista never had the LC test"

Provista had that test, called LC Sentinel, when Gartner was CEO of Provista. LC Sentinel was Radient's DR-70 with a different name. When Gartner left Provista and Reese became CEO, Provista abandoned DR-70.

This article proves that Provista DX is still doing the lung cancer LC Sentinel test for breast and lung cancer..Can you show us where ProvistsDX dropped it..It 100 percent appears that GCDX is going to be their subsidiary for that part of their organization, mainly focused on Lung Cancer until William gets FDA approval.

IT DOESN't APPEAR IN THIS ARTICLE HE ABANDONED THE TEST FOR LUNG CANCER..Can you prove where PRovista stated that they abandoned DR-70...If they were abandoning it why was GCDX pursuing the DR-70 on behalf of ProvistaDx..Why would 34 Angel Investors pay William for HIS Lung Test and then dtop it?


Provista to go public with breast, lung cancer testing technology

by Joan Koerber-Walker on December 31, 2011 in AZBio News, Members

Phoenix Business Journal, Friday, December 30, 2011

by Linda Obele, Contributing Writer
The Great Recession seems to have been more of a nuisance than a hindrance to Provista Life Sciences .

“The recession only affected us from the standpoint that it became more work to raise capital,” said Gartner, whose 8-year-old company brought a breast cancer blood test to market in 2009 and is working on similar diagnostics for lung cancer and Alzheimer’s disease. “In the phase we were in, it’s not like the economy reduced our revenue — we didn’t have a product to sell yet.”

Recently, Gartner sold Phoenix-based Provista Life Sciences LLC’s breast and lung cancer testing technologies to a new company called Provista Diagnostics Inc., which he intends to take public by the middle of next year.

The lung cancer blood test still is in clinical trials, but Gartner hopes the new company will help the breast cancer blood test penetrate the commercial market.

Meanwhile, Provista Life Sciences will continue developing neurological-disorder diagnostic tools, such as the blood test to help doctors detect Alzheimer’s disease, which is not yet on the market.

Gartner said he wasn’t bothered much by the lack of venture capital funding that occurred during the recession, preferring instead to work with equity capital firms, angel investors and family institutional investors.

“The money was there, but people were scared and they took longer to make a decision,” he said.



DCMAN..here is some of the great DD that I have collected over the last 4 years..Here is one on Provista DX and William and Provista Life Sciences. According to the article WILLIAM SOLD THE BREAST AND LUNG CANCER TO PROVISTA DX. Which means GCDX is Provista DX and William is still Provista DX..